Evidence map›Paper›PMID 40809951›Full record

ArticleEJHaem2025

Life-Threatening Cytopenias in a Jehovah's Witness Following CD19-Directed Chimeric Antigen Receptor T Cell Therapy.

Corinne J Shamehdi, Christian A Gordillo, Ahmed Sawas, Rodney Macedo, Markus Y Mapara, Ran Reshef

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJHaem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Corinne J ShamehdiNew York Presbyterian Hospital New York New York USA.ORCID https://orcid.org/0009-0006-1263-829X
Christian A GordilloBlood and Marrow Transplantation and Cell Therapy Program Columbia University Irving Medical Center New York New York USA.ORCID https://orcid.org/0000-0003-4829-1954
Ahmed SawasDivision of Hematology & Oncology Columbia University Irving Medical Center New York New York USA.
Rodney MacedoColumbia Center for Translational Immunology Columbia University Irving Medical Center New York New York USA.
Markus Y MaparaBlood and Marrow Transplantation and Cell Therapy Program Columbia University Irving Medical Center New York New York USA.
Ran ReshefBlood and Marrow Transplantation and Cell Therapy Program Columbia University Irving Medical Center New York New York USA.ORCID https://orcid.org/0000-0003-2185-9546

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here we report on a Jehovah's Witness (JW) patient who experienced profound and prolonged life-threatening cytopenias following CD19-targeted CAR T cell therapy, successfully managed with bloodless medicine strategies. This case highlights the potential risks of CAR T therapy, even in patients without known hematotoxicity risk factors. By implementing tailored bloodless strategies, the patient received CAR T therapy without significant infectious, cardiac, or bleeding complications. Remarkably, they remain in remission 5 years later with normal blood counts. This underscores the viability of CAR T cell therapy for JW patients, emphasizing the importance of careful patient selection and risk-benefit deliberation. Further research into severe cytopenias post-CAR T therapy is critically needed.

Indexed as

cell therapycytopeniaJehovah's witnesslymphomas

Identifiers

PMID40809951
PMCPMC12345917

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.